Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study.

Abstract

BACKGROUND:

Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small cell lung cancer (NSCLC). This retrospective analysis was performed to assess the efficacy of icotinib on patients with non-small-cell lung cancer (NSCLC).

METHODS:

82 consecutive patients treated with icotinib as first (n = 24) or second/third line (n = 58) treatment at three hospitals in Nanjing were enrolled into our retrospective research. The Response Evaluation Criteria in Solid Tumors (RECIST) was used to evaluate the tumor responses and the progression-free survival (PFS) and overall survival (OS) was evaluated by the Kaplan-Meier method.

RESULTS:

Median PFS was 4.0 months (95% CI 2.311-5.689). Median OS was 11.0 months (95% CI 8.537-13.463) in this cohort. Median PFS for first and second/third line were 7.0 months (95% CI 2.151-11.8) and 3.0 months (95% CI 1.042-4.958), respectively. Median OS for first and second/third line were 13.0 months (95% CI 10.305-15.695) and 10.0 months (95% CI 7.295-12.70), respectively. In patients with EGFR mutation (n = 19), icotinib significantly reduced the risk of progression (HR 0.36, 95% CI 0.18-0.70, p = 0.003) and death (HR 0.10, 95% CI 0.02-0.42, p = 0.002) compared with those EGFR status unknown (n = 63). The most common adverse events were acne-like rash (39.0%) and diarrhea (20.7%).

CONCLUSIONS:

Icotinib is active in the treatment of patients with NSCLC both in first or second/third line, especially in those patients harbouring EGFR mutations, with an acceptable adverse event profile.

• Authors: Xiaofeng Chen, Quan Zhu, Yiqian Liu, Ping Liu, Yongmei Yin, Renhua Guo, Kaihua Lu, Yanhong Gu, Lianke Liu, Jinghua Wang, Zhaoxia Wang, Oluf Dimitri Røe, Yongqian Shu, Lingjun Zhu
• Journal: PloS one (PLoS One) Vol. 9 Issue 5 Pg. e95897 ( 2014) ISSN: 1932-6203 [Electronic] United States
• PMID: 24836053 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Crown Ethers
• Quinazolines
• icotinib
• ErbB Receptors

Topics

• Aged
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• China
• Crown Ethers (therapeutic use)
• Disease-Free Survival
• ErbB Receptors (antagonists & inhibitors)
• Humans
• Kaplan-Meier Estimate
• Middle Aged
• Quinazolines (therapeutic use)
• Retrospective Studies
• Treatment Outcome